Epirus: Leerink Global Healthcare Conference (Epirus Biopharmaceuticals) - Mar 21, 2015 - "58 Week Data - Patients can be Started and Maintained and Safely Switched From Remicade"; Open Label Phase - 58 weeks: Durability of response maintained out to 58 weeks with BOW015 alone and after switching from Remicade, BOW015 safe and well tolerated alone and after switching from Remicade, Consistent immunogenicity between arms: BOW015 alone and BOW015 switched from Remicade" "
P3 data • Biosimilar
|